This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...

The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib–venetoclax and ...

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...